Cancer Center Support Grant
Cancer Center Support Grant
批准号:
8473787
负责人:
GARTH POWIS
金额:
$371.01万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-05-01 至 2015-04-30
关键词:
ApoptosisAreaBasic Cancer ResearchBasic ScienceBiologyBlood VesselsBudgetsCancer BiologyCancer CenterCancer Center Support GrantCancer EtiologyCell AdhesionCell DeathCellular biologyChemicalsDevelopmentDiagnosisDiseaseEvaluationFacultyFundingFutureGlycobiologyGoalsGrantHealthHumanHuman ResourcesInstitutesInstructionInterdisciplinary StudyKnowledgeLaboratory ResearchLeadMalignant NeoplasmsMeasuresMedicineMissionMolecularMolecular ProbesMovementNIH Grants and ContractsNamesPathogenesisPreventionProcessPublicationsPublishingRecruitment ActivityResearchResearch ActivityResearch InfrastructureResearch InstituteResource SharingResourcesScientistSignal TransductionStem cellsStructureUnited States National Institutes of Healthanticancer researchbasecancer geneticscancer preventioncancer therapyforgingintercellular communicationmembernovel strategiesprogramsresearch and developmentstemtumortumor microenvironment
中文摘要
项目总结(见说明):
伯纳姆研究所的癌症中心,其中构成了近90%的研究所的预算和人员在拉霍亚,加利福尼亚州,一直是一个收件人的癌症中心支持赠款连续自1981年以来。癌症中心的使命是开展旨在了解人类癌症发病机制的尖端合作基础研究,并促进基础研究成果的运动
癌症预防、诊断和治疗的新策略。
伯纳姆的癌症中心自上次更新以来一直保持着强劲的发展势头。伯纳姆目前在全国所有研究机构中排名第四,在全球20大科学影响力组织中排名第四。自上次更新以来,癌症中心已发表了超过1,500篇出版物,其中20%是合作出版的。癌症中心进一步
增强了其在细胞粘附、糖生物学、癌症遗传学、细胞信号传导和细胞死亡研究领域的科学突出地位。新兴的卓越领域包括肿瘤发展中的血管生物学和干/祖细胞生物学。化学生物学的一个首要主题已经在我们的基础癌症研究与癌症治疗的分子探针和铅分子的开发之间建立了重要的联系。自上次更新以来,已招聘了21名新教师,
正式成员增至56名(增加27%)。我们的拨款基础增加了60%,从5100万美元增加到8200万美元,合作赠款占我们今天所有NIH拨款的55%,而2003年为25%。总的来说,癌症中心44%的赠款来自NCI和其他癌症机构。
通过深入的规划和评估过程,癌症中心现在有一个修订后的计划,
它由四个高度合作和跨学科的项目组成,分别是肿瘤微环境,肿瘤发育,信号转导和细胞凋亡与细胞死亡研究。该计划由一个由9个共享资源组成的基础设施支撑。我们增强的化学生物学基础设施不仅有助于我们自己的科学家的使命,
全国性的资源,由NIH和NCI的几项赠款和合同支持。展望未来,我们在本申请中描述的计划旨在进一步提高我们在高影响基础癌症生物学方面的声誉,并利用我们的化学生物学计划加强我们的基础癌症研究与我们希望在未来癌症的预防,诊断和治疗方面取得越来越大的成就之间的联系。
英文摘要
PROJECT SUMMARY (See instructions):
Burnham Institute's Cancer Center, which constitutes nearly 90% of the Institute's budget and personnel in La Jolla, CA, has been a recipient of the Cancer Center Support Grant continuously since 1981. The mission of the Cancer Center is to perform cutting-edge, collaborative basic research aimed towards understanding the pathogenesis of human cancer, and to promote the movement of basic research findings
into novel strategies for cancer prevention, diagnosis, and therapy.
Burnham's Cancer Center has continued on a strong trajectory since the last renewal. Burnham currently ranks 4th in NIH funding among all research institutes in the nation, and among top 20 organizations worldwide for its scientific impact measured by citations per publications. The Cancer Center has published >1,500 publications since the last renewal, of which 20% were collaborative. The Cancer Center has further
enhanced its scientific prominence in the areas of cell adhesion, glycobiology, cancer genetics, cell signaling, and cell death research. Emerging areas of excellence include vascular biology and stem/progenitor cell biology in tumor development. An overarching theme of Chemical Biology has forged significant connections between our basic cancer research and the development of molecular probes and lead molecules for cancer therapy. 21 new faculty have been recruited since last renewal, bringing the
number of full members to 56 (27% increase). Our grant base has increased by 60%, from $51 MM to $82MM, and collaborative grants constitute ~55% of all our NIH grant funding today, compared to 25% in 2003. Altogether, 44% of the Cancer Center's grants come from NCI and other cancer agencies.
Through an in-depth planning and evaluation process, the Cancer Center has now a revised program
structure, and consists of four highly collaborative and interdisciplinary Programs, named Tumor Microenvironment, Tumor Development, Signal Transduction, and Apoptosis & Cell Death Research. The Programs are buoyed by an underlying infrastructure that consists of 9 Shared Resources. Our enhanced Chemical Biology infrastructure not only aids the mission of our own scientists, but has also become a
nation-wide resource supported by several grants and contracts from NIH and NCI. Going forward, our plans described in this application seek to further enhance our reputation in high-impact basic cancer biology, and to leverage our Chemical Biology Initiative to strengthen the linkage between our basic cancer research and our desire to make an increasingly substantial mark on the prevention, diagnosis, and treatment of cancer in the future.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting ERK5 for Colorectal Cancer Therapy
-
批准号:10021322
-
项目类别:
-
资助金额:$27.35万
-
财政年份:2020
-
负责人:GARTH POWIS
-
依托单位:
Targeting ERK5 for Colorectal Cancer Therapy
-
批准号:10357462
-
项目类别:
-
资助金额:$16.95万
-
财政年份:2020
-
负责人:GARTH POWIS
-
依托单位:
Inhibiting Multi-Functional ALDOA for Cancer Therapy
-
批准号:10357451
-
项目类别:
-
资助金额:$50.46万
-
财政年份:2018
-
负责人:GARTH POWIS
-
依托单位:
Inhibiting Multi-Functional ALDOA for Cancer Therapy
-
批准号:10494262
-
项目类别:
-
资助金额:$49.81万
-
财政年份:2018
-
负责人:GARTH POWIS
-
依托单位:
PLEKHA7 A Novel Target for Mutant KRAS Therapy
-
批准号:8964895
-
项目类别:
-
资助金额:$62.41万
-
财政年份:2015
-
负责人:GARTH POWIS
-
依托单位:
PLEKHA7 A Novel Target for Mutant KRAS Therapy
-
批准号:9301505
-
项目类别:
-
资助金额:$62.41万
-
财政年份:2015
-
负责人:GARTH POWIS
-
依托单位:
PLEKHA7 A Novel Target for Mutant KRAS Therapy
-
批准号:9485728
-
项目类别:
-
资助金额:$8.28万
-
财政年份:2015
-
负责人:GARTH POWIS
-
依托单位:
PLEKHA7 and beta-catenin interact to regulate mutant KRas
-
批准号:9251596
-
项目类别:
-
资助金额:$7.03万
-
财政年份:2015
-
负责人:GARTH POWIS
-
依托单位:
Hypoxia and Anticancer Drug Action
-
批准号:8637740
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2013
-
负责人:GARTH POWIS
-
依托单位:
Inhibiting oncogenic KRAS for cancer therapy
-
批准号:8637741
-
项目类别:
-
资助金额:$38.03万
-
财政年份:2013
-
负责人:GARTH POWIS
-
依托单位:
Redox Signaling and Cancer Drug Action
-
批准号:8637738
-
项目类别:
-
资助金额:$32.65万
-
财政年份:2013
-
负责人:GARTH POWIS
-
依托单位:
Exploiting tumor stroma interactions for cancer therapy
-
批准号:8637688
-
项目类别:
-
资助金额:$38.03万
-
财政年份:2013
-
负责人:GARTH POWIS
-
依托单位:
Exploiting tumor stroma interactions for cancer therapy
-
批准号:8842459
-
项目类别:
-
资助金额:$40.46万
-
财政年份:2013
-
负责人:GARTH POWIS
-
依托单位:
Inhibiting oncogenic KRAS for cancer therapy
-
批准号:8685191
-
项目类别:
-
资助金额:$39.25万
-
财政年份:2013
-
负责人:GARTH POWIS
-
依托单位:
Inhibiting oncogenic KRAS for cancer therapy
-
批准号:8842939
-
项目类别:
-
资助金额:$40.46万
-
财政年份:2013
-
负责人:GARTH POWIS
-
依托单位:
Exploiting tumor stroma interactions for cancer therapy
-
批准号:8217439
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2012
-
负责人:GARTH POWIS
-
依托单位:
Inhibiting oncogenic KRAS for cancer therapy
-
批准号:8292831
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2012
-
负责人:GARTH POWIS
-
依托单位:
Chemoprevention by a Targeted Thioredoxin Inhibitor.
-
批准号:7629721
-
项目类别:
-
资助金额:$31.96万
-
财政年份:2008
-
负责人:GARTH POWIS
-
依托单位:
Chemoprevention by a Targeted Thioredoxin Inhibitor.
-
批准号:7837614
-
项目类别:
-
资助金额:$31.96万
-
财政年份:2008
-
负责人:GARTH POWIS
-
依托单位:
Chemoprevention by a Targeted Thioredoxin Inhibitor.
-
批准号:8061629
-
项目类别:
-
资助金额:$31.0万
-
财政年份:2008
-
负责人:GARTH POWIS
-
依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
-
批准号:2021JJ40433
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:孙磊
-
依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
-
批准号:32001603
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:段真珍
-
依托单位:
AREA国际经济模型的移植.改进和应用
-
批准号:18870435
-
项目类别:面上项目
-
资助金额:2.0万元
-
批准年份:1988
-
负责人:史树中
-
依托单位: